Class C software-only IVD supports European rollout of a JCO-published assay designed to bring clinically validated prognostic assessment into routine breast cancer care
June 23, 2026
A Digital Publication for the Practicing Medical Specialist, Industry Executive, & Investor
Class C software-only IVD supports European rollout of a JCO-published assay designed to bring clinically validated prognostic assessment into routine breast cancer care